Quest Summer/Fall 2015 : Page 2

Funding a Major Research Project: Prostate Cancer SPORE Grant Awarded… Impact on patients The overall objective of the SPORE proposal is to conduct studies that impact the outcomes and overall quality of life of prostate cancer patients. Dr. Catalona and his collaborators proposed four major research projects that involve two of the most important issues in prostate cancer: • Determining germline genetic variations that help identify which prostate cancer patients need immediate treatment and which can be managed with active surveillance. • Addressing the need for new treatments for men with advanced cancer that no longer responds to current therapy. See the Winter 2014 Q UEST (Volume 22, Number 3, Page 2) for information on the SPORE’s proposed research projects. (Continued from page 1.) “We are delighted that, through an incredible team effort, we achieved this prestigious SPORE award, especially in the present difficult climate for securing NIH research funding. This SPORE represents a major investment by the NCI in our prostate cancer research program. Our SPORE unites basic scientists, clinicians, pathologists, biostatisticians, bioinformaticists and advocates, working together to understand the basic biology of prostate cancer and design and conduct innovative paradigm-shifting clinical trials. We are excited and anticipate that the results obtained through our SPORE will have a significant impact on the outcomes and overall quality of life of prostate cancer patients and their families.” -Dr. Catalona Contact Information for Dr. Catalona Office Number: 312-695-4471 The SPORE team The SPORE is a collaboration between Northwestern University’s Robert H. Lurie Comprehensive Cancer Center, the University of Chicago’s Comprehensive Cancer Center and NorthShore University Health System, with contributions from the University of California San Francisco, the University of In nature, what lies beneath the surface is often Pittsburgh and the University of most essential. Southern California. The SPORE ICPCG Research is fully integrated into a rich research environment that both strengthens the Confirming the Role of Genetic proposed research and leverages Variants and Familial Disease resources available for the planned he ICPCG research group, of which projects. Dr. Catalona is a contributor, Dr. Catalona is Director of Prostate analyzed 25 prostate cancer genetic Cancer Research at the Robert H. Lurie variants and their association with familial prostate cancer risk. Comprehensive Cancer Center. Dr. The genome-wide association study Walter Stadler, Co-Principal Investigator included 12,506 samples, including of the SPORE, serves as Deputy Director 9,560 prostate cancer cases (3,368 with of the University of Chicago’s aggressive disease). For people with Comprehensive Cancer Center. Robin G family history of prostate cancer, 20 of Leikin, Ph.D., is the Scientific the 25 genetic variants were at least Administrator of the grant. The SPORE nominally associated with prostate cancer. Sixteen variants had significant benefits from institutional and associations with prostate cancer. For philanthropic support from the men with aggressive disease, 16 of the Urological Research Foundation and variants had at least nominal association NorthShore University Health System to with prostate cancer and 8 were augment funding from the National statistically significant. Cancer Institute. These results indicate that the There are currently seven other majority of common, low-risk variants Prostate Spores, including Dana-Farber previously identified for prostate cancer also contribute to risk for familial Harvard Cancer Institute, Fred prostate cancer, and some may increase Hutchinson Cancer Research Center, the risk of aggressive disease. Johns Hopkins University, Memorial Teerlink CC, Thibodeau SN, McDonnell SK, et al.; International Sloan-Kettering Cancer Center, UCLA, Consortium for Prostate Cancer Genetics. Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate the University of Michigan and the Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. Hum Genet. 2014 Mar;133(3):347-56. University of Texas/MD Anderson. doi:10.1007/s00439-013-1384-2. Epub 2013 Oct 26. T Q uest The mission of the Urological Research Foundation is to support research and patient education in prostate cancer. Q UEST is a free newsletter, but we need and appreciate your voluntary contributions. Q UEST is published three times a year by the Urological Research Foundation. ©2015 Urological Research Foundation No material reproduced without permission. Circulation: 42,000 Medical Editor: William J. Catalona, M.D. Editor: Betsy Haberl Graphics: Amy L. Davis 2 If you are reading Q UEST for the first time and would like to receive future issues, please send your name and address to: Q UEST , PO Box 855, Manchester, MO 63011 . To receive Q UEST by email, please send your request to URF@drcatalona.com. Find Q UEST online at: www.drcatalona.com Q UEST Summer/Fall 2015 ©Dan Oldfield

Previous Page  Next Page


Publication List
Using a screen reader? Click Here